Question explored with the scientific record
Should over 75s take statins
For people over 75 who already have heart disease, statins clearly reduce mortality. For those without it, the benefit is smaller and the harms are real.
The evidence for secondary prevention (after a heart attack or stroke) is strong. A large UK study of over 12,000 older patients found that statins after a heart attack cut all-cause mortality by about 38% in people aged 60-79 [4]. The benefit shrank to a 23% reduction in those 80 and older, and the study found no clear reduction in repeat heart attacks for that oldest group [4]. A separate review of older adults with established cardiovascular disease found that higher-intensity statin use was linked to lower mortality (HR 0.85) compared to low-dose or no statins [5].
For primary prevention (no existing disease), the picture is murkier. The JUPITER trial found that rosuvastatin reduced major cardiovascular events by 39% in people over 70 with elevated inflammation markers, but it did not significantly lower total mortality in that age group [5, 6]. A major meta-analysis from the Cholesterol Treatment Trialists found that for people over 75 with no known vascular disease, statins reduced major vascular events by only 8%, and that result was not statistically significant [6]. The confidence interval was wide (0.73 to 1.16), meaning the data is compatible with no benefit at all.
The harms matter. Statins increase the risk of new-onset diabetes by about 60% (OR 1.61) [2]. In the JUPITER trial, for every 54 people who developed diabetes on rosuvastatin, 134 vascular events were avoided, but that trade-off is less favorable in older people with lower baseline risk [1]. Statin-associated muscle symptoms affect 10-30% of users in observational studies, though randomized trials report lower numbers [3]. In people over 80, statin use was linked to a near-doubling of falls and fractures (HR 1.82 and 1.91) [4].
The evidence for dementia prevention is weak. One study found that starting statins made no difference to dementia risk over 10 years, though sustained use showed a small, non-significant trend toward lower risk [7].
| Group | Outcome | Statin benefit | Harm notes |
|---|---|---|---|
| 60-79, after heart attack | All-cause mortality | 38% reduction | Falls/fractures not elevated |
| 80+, after heart attack | All-cause mortality | 23% reduction | Falls/fractures nearly doubled |
| 75+, no heart disease | Major vascular events | 8% (not significant) | Diabetes risk up 60% |
My call: for people over 75 with established cardiovascular disease, statins are worth taking. For those without it, the evidence does not support routine use. The benefit is small, uncertain, and comes with real risks of diabetes, muscle pain, and falls. Confidence: moderate.
Sources used 7
-
Balancing the cardiometabolic benefits and risks of statins
A Lancet commentary assessing the balance between the cardiovascular benefits and the diabetogenic risk of statins, especially rosuvastatin in the JUPITER primary-prevention trial, and arguing for risk-aware prescribing, monitoring, and further mechanistic and population-specifi…
DOI: 10.1016/S0140-6736(12)61301-4 -
Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis
A meta-analysis of 11 studies (236,864 subjects) found statin use was associated with a small but statistically significant increased risk of new-onset diabetes mellitus (fixed-effects OR 1.61, 95% CI 1.55-1.68; p < 0.001).
DOI: 10.1159/000485196 -
Statin Toxicity
A comprehensive, mechanistic review of statin toxicity with a focus on statin-associated muscle symptoms (SAMS), detailing the mevalonate pathway effects, mitochondrial and calcium signaling perturbations, genetic factors, clinical presentations, prevalence, potential biomarkers…
DOI: 10.1161/circresaha.118.312782 -
Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study
Statins after myocardial infarction in a large real-world cohort of older UK patients reduce recurrent MI and all-cause mortality in 60–79-year-olds, show no clear recurrence benefit in 80+, and are linked to higher falls and fractures among the oldest, with age-dependent cost i…
DOI: 10.1093/gerona/glw082 -
Should statin therapy be used in medication of elderly patients?
The author concludes that statin therapy is useful in elderly patients, with mandatory use in secondary prevention and lower, individually adjusted doses in primary prevention, while excluding patients with terminal illness, frailty, or dialysis.
DOI: 10.5937/galmed2202065d -
Statin Therapy for Primary and Secondary Prevention in Older Adults
Evidence supports statin therapy for secondary prevention in older adults and for primary prevention in selected high-risk older patients; age alone should not deter statin therapy.
DOI: 10.1007/s11883-024-01257-9 -
Emulating a target trial of statin use and risk of dementia using cohort data
Emulating a target trial in the Rotterdam Study, statin initiation showed little 10-year dementia risk difference, while sustained statin use was associated with reduced risks of dementia and dementia or death, though residual confounding and wide CIs limit interpretation.
DOI: 10.1212/wnl.0000000000010433